I'm LongbridgeAI, I can summarize articles.Hong Kong investors are bifurcating capital in 2026, driving defensive dividend ETFs up over 15% while selectively funding enterprise AI operators and clinical-stage biotech debuts amid structural market shifts.
Capital flows in Hong Kong are increasingly bifurcating in mid-2026, with investors piling into defensive, high-yield assets while selectively backing robust new entrants in artificial intelligence and biotechnology, according to people familiar with the matter. The market is nearing an inflection point as institutional funds aggressively reallocate their portfolios in response to shifting macroeconomic conditions.
Ping An of China CSI HK Dividend ETF (3070.HK)
Defensive equity plays are capturing significant inflows amid broader market volatility. The Ping An of China CSI HK Dividend ETF surged more than 15% in July 2026. Portfolio managers are targeting the third quarter as a critical window for dividend allocations, particularly leaning on the stability of energy and financial constituents.
CSOP Nikkei 225 Index ETF (3153.HK)
Driven by an ongoing appetite for cross-border diversification, investment funds continue to utilize the CSOP Nikkei 225 Index ETF as a liquid channel to access overseas equities. The ETF provides a vital offshore hedge for investors navigating concentrated domestic risks.
Wenge Technology (1956.HK)
Enterprise AI developers are raising fresh capital at premium valuations. Wenge Technology, which commanded a 10.2% share of China's enterprise AI decision-intelligence market in 2025, debuted on the HKEX in June 2026. The offering drew USD 31M from cornerstone investors, sending the stock soaring over 105% intraday on its opening day.
GDS Holdings (9698.HK)
Infrastructure operators are scaling operations to meet AI-driven data demands. GDS Holdings reported in July that its renewable energy usage hit 60%. According to people familiar with the matter, the company is also considering a roughly USD 500M IPO in the US for its international division.
HBM Holdings (2142.HK)
Clinical catalysts are driving targeted rallies in the biotech sector. HBM Holdings secured NMPA approval for its asthma IND in July 2026, shortly after winning a USD 20.2M patent dispute in the US. The company expects these developments to compound the momentum from a strong previous quarter, where revenue jumped 294.2% to HKD 220.4M.
JBM Healthcare (2161.HK)
Traditional healthcare brands are identifying new growth metrics via digital expansion. JBM Healthcare reported fiscal year revenue of HKD 835M, up 6.7%, with net profit reaching HKD 201M. The company is targeting further margin expansion beyond its current 55.8% by scaling its cross-border Tmall Global operations.
MAOGEPING (1318.HK)
Premium consumer brands are defending their market share through aggressive domestic retail execution. High-end cosmetics group MAOGEPING reported a 41.0% revenue jump to RMB 1.97B in the first half of 2024, signaling robust resilience in core product demand.
Lopal (2465.HK)
EV supply chain manufacturers are racing to upgrade their technological offerings. Lopal initiated trial production at its 110,000-ton cathode facility and previously launched a next-generation coolant in 2025. The company recently garnered a buy rating from UBS.
Dah Sing Banking Group (2356.HK)
Traditional cyclicals are navigating a highly complex rate environment. While Hong Kong's banking sector saw total assets climb to HKD 26T in 2025, shrinking net interest margins have prompted lenders like Dah Sing Banking Group to cautiously manage an industry-wide NPL ratio of 2.14%.
China Eastern Airlines (0670.HK)
Aviation operators are bracing for a sustained cross-border travel recovery. China Eastern Airlines is targeting operational efficiency upgrades as the carrier absorbs returning international passenger traffic and actively restructures its broad fleet capacity.
This article does not constitute investment advice.